Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
12. November 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a...
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
07. November 2024 09:05 ET
|
Clearside Biomedical, Inc.
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space...
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
06. November 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
04. November 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
31. Oktober 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
22. Oktober 2024 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of...
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
09. Oktober 2024 06:30 ET
|
Clearside Biomedical, Inc.
- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not...
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
27. August 2024 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector® - - Topline Data Expected to be Reported During the Week of October...
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
12. August 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse...
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08. August 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...